Table 2.
Voxel | Drug | Tissue | TD | ASD | F(dof) | p-value |
---|---|---|---|---|---|---|
BG | PLC | GM (SD) | 42.53% (3.03%) | 45.43% (3.21%) | F(1) = 7.307 | 0.011 |
WM (SD) | 50.47% (3.39%) | 46.54% (4.08%) | F(1) = 9.345 | 0.004 | ||
CSF (SD) | 6.92% (1.33%) | 7.95% (1.95%) | F(1) = 3.222 | 0.082 | ||
CBDV | GM (SD) | 41.65% (2.40%) | 44.68% (3.47%) | F(1) = 6.70 | 0.016 | |
WM (SD) | 51.71% (2.95%) | 47.23% (4.94%) | F(1) = 7.89 | 0.010 | ||
CSF (SD) | 6.56% (1.36%) | 8.01% (2.48%) | F(1) = 3.42 | 0.077 | ||
DMPFC | PLC | GM (SD) | 52.93% (2.21%) | 52.38% (3.49%) | F(1) = 0.299 | 0.589 |
WM (SD) | 27.24% (3.36%) | 28.11% (3.65%) | F(1) = 0.527 | 0.473 | ||
CSF (SD) | 19.73% (4.05%) | 19.41% (2.57%) | F(1) = 0.076 | 0.784 | ||
CBDV | GM (SD) | 52.68% (3.16%) | 53.41% (3.67%) | F(1) = 0.30 | 0.590 | |
WM (SD) | 27.94% (4.23%) | 27.52% (4.13%) | F(1) = 0.07 | 0.802 | ||
CSF (SD) | 19.25% (5.13%) | 18.97% (2.22%) | F(1) = 0.03 | 0.857 |
ASD Autism spectrum disorder, BG Basal ganglia, CBDV Cannabidivarin, CSF Cerebrospinal fluid, DMPFC Dorsomedial prefrontal cortex, F(dof) F-value and degrees of freedom, GM Grey matter, PLC Placebo, SD Standard deviation, TD Typically developing controls, WM White matter